Pharmadrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen says the sale of the company’s German cannabis assets to Khiron Life Sciences takes it one step closer to streamlining its focus into a pure-play biotech company.

Following the closing of the sale of the cannabis assets, Cohen told Proactive that Pharmadrug’s priority is on advancing PD-001, its patented version of cepharanthine, towards potential FDA clinical trials on both the oncology and antiviral fronts.

Pharmadrug will soon update investors on the latest developments with cepharanthine, he added.